Extendicare Inc. (TSE:EXE – Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as C$11.35 and last traded at C$11.31, with a volume of 84376 shares trading hands. The stock had previously closed at C$11.12.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on EXE shares. BMO Capital Markets set a C$11.00 price target on Extendicare and gave the company a “market perform” rating in a report on Thursday, January 30th. TD Securities lifted their price target on Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada lifted their price target on Extendicare from C$9.50 to C$11.00 and gave the company a “sector perform” rating in a report on Thursday, November 28th.
View Our Latest Research Report on Extendicare
Extendicare Stock Performance
Extendicare Announces Dividend
The company also recently announced a monthly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 17th will be issued a dividend of $0.04 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.48 annualized dividend and a yield of 4.23%. Extendicare’s payout ratio is 61.20%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
See Also
- Five stocks we like better than Extendicare
- Canadian Penny Stocks: Can They Make You Rich?
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- 3 Grocery Stocks That Are Proving They Are Still Essential
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- ETF Screener: Uses and Step-by-Step Guide
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.